A review of cancer risk prediction models with genetic variants.
Xuexia Wang, Michael J Oldani, Xingwang Zhao...
https://pubmed.ncbi.nlm.nih.gov/25288876/Actively Recruiting
Led by HALO Diagnostics · Updated on 2022-10-14
2000
Participants Needed
1
Research Sites
521 weeks
Total Duration
Researchers are conducting the Phase I Human Analytics HALO Study to improve diagnosis and risk prediction for cardiovascular diseases, cancer, dementia, traumatic brain injury, and other disorders. The study uses machine learning and data analysis techniques on electronic medical records to detect subtle patterns, aiming to diagnose diseases earlier and more accurately. The research also focuses on developing multivariate biomarker risk scores and directing participants to relevant clinical trials based on physician review. This observational study involves no interventions and includes groups of patients diagnosed with dementia, prostate cancer, breast cancer, traumatic brain injury, and patients without any diagnosed condition. Data analysis will be applied to all available biomarkers and health determinants to enhance diagnostic confidence and reduce time to diagnosis. Participants are observed over time, with no treatments administered as part of the study. Participants will be monitored through clinical evaluations, biomarker assessments, and data analysis to assess prostate cancer staging, Gleason scores, and mortality over up to five years. Additional outcomes include measurements of urinary symptoms, erectile function, emotional well-being, and incontinence levels. The study collects comprehensive health data to improve diagnosis and risk stratification, with participant involvement lasting several years for long-term monitoring and evaluation.
CONDITIONS
Phase I Human Analytics (HALO) Study
C
Christopher R Hancock, MD,MBA
E
Erik W Peterson
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
HALO Diagnostics
Lead Sponsor
HALO Affiliate Sites
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed over time to collect data from electronic medical records and other sources to improve diagnostic accuracy and risk stratification for various diseases including cardiovascular, cancer, dementia, and brain injury.
Periodic visits depending on cohort assignment and physician recommendation
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Xuexia Wang, Michael J Oldani, Xingwang Zhao...
https://pubmed.ncbi.nlm.nih.gov/25288876/Stephen F Weng, Jenna Reps, Joe Kai...
https://pubmed.ncbi.nlm.nih.gov/28376093/HALO Diagnostics
Lead Sponsor
HALO Affiliate Sites
Collaborating Sponsor